Efficacy of rosuvastatin for the treatment of Non-alcoholic fatty liver disease with hyperlipidemia
- Conditions
- on-alcoholic fatty liver disease with hypercholesterolemia
- Registration Number
- JPRN-UMIN000008075
- Lead Sponsor
- Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Not provided
1) Patients with hypersensitivity to HMG-CoA reductase inhibitor (statin) 2) Uncontrolled diabetes 3) Viral or autoimmune liver disease 4) Patients with severe liver dysfunction(ALT or AST > 100 IU/L or total bilirubin > 2.5 mg/dL or ALB < 3.5g/dl or PT < 70% or PLT < 100,000/ul) 5) Patients with renal dysfunction (the serum creatinine more than 2.0 mg/dL or Ccr<30mL/min/1.73mm) 6) Patients on treatment with cyclosporine 7) Pregnant and potential pregnancy 8) Patients with hypothyroidism, hereditary myopathy (muscular dystrophy) or family history of hereditary myopathy, and drug-induced myopathy 9) Patients with drug abuse or alcoholism 10) Patients who are ineligible for any other reason in the opinion of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent change of liver transaminases composition in 6 months
- Secondary Outcome Measures
Name Time Method 1) Percent change of lipid profile in 6 months 2) Low-density lipoprotein cholesterol goal achievement ratio recommended by the Japan Atherosclerosis Society(JAS) in 6 months